3、公司目前大客户占销售收入比例有多少？当前养殖利润 较低情况下，公司预计下半年销量是否能有提升？ 投资者您好，公司目前直销模式占销售收入比例约 60%左 右。随着公司与头部大型养殖集团的深度战略合作以及宠物、 家畜板块等新产品持续上市，公司预计下半年销量会有所提 升。请您持续关注公司公告，感谢关注。 证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：2023-005 | | □特定对象调研 □ 分析师会议 | | --- | --- | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | 类别 | 新闻发布会 路演活动 □ □ | | | 现场参观 □ | | | □ 其他 （请文字说明其他活动内容） | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 (周二) 下午 2023 9 5 13:30~16:50 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 董事长 李守军 董事会秘书 ...

因长沙经济技术开发区对公司控股子公司湖南中岸生物药业有限公司（以下简称 "湖南中岸"）原位于长沙经济技术开发区的厂区所在区域重新统一规划，湖南中岸 已移址至浏阳经济技术开发区并完成新厂建设。经审议，同意湖南中岸与长沙经济技 术开发区投资控股有限公司（以下简称"长沙经开投控"）签订《土地使用权及地上 建（构）筑物转让合同》，将湖南中岸位于长沙经济技术开发区板仓南路的两宗工业 用地使用权及地上房屋、构筑物及附属设施、设备等资产转让给长沙经开投控，转让 款由评估补偿价格和标的物转让所产生的增值税及增值税附加费用等两部分组成，其 中评估补偿价格为人民币 158,967,863 元；标的物转让所产生的增值税及增值税附加 费用、印花税预计为人民币 9,273,526 元（最终金额以税务部门最终核算为准）由长 沙经开投控代缴至税务机关。 证券代码：300119 证券简称：瑞普生物 公告编号：2023-061 天津瑞普生物技术股份有限公司 第五届董事会第八次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 天津瑞普生物技术股份有限公 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-062 天津瑞普生物技术股份有限公司 关于出售资产的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 重要提示内容： 因长沙经济技术开发区对天津瑞普生物技术股份有限公司（以下简称"公 司"）控股子公司湖南中岸生物药业有限公司（以下简称"湖南中岸"）原位于 长沙经济技术开发区的厂区所在区域重新统一规划，湖南中岸已移址至浏阳经济 技术开发区并完成新厂建设，故湖南中岸拟将其位于长沙经济技术开发区板仓南 路的两宗工业用地使用权及地上房屋、构筑物及附属设施、设备等资产（以下简 称"标的资产"）转让给长沙经济技术开发区投资控股有限公司（以下简称"长 沙经开投控"），转让款由评估补偿价格和标的物转让所产生的增值税及增值税 附加费用等两部分组成，其中评估补偿价格为人民币158,967,863元；标的物转 让所产生的增值税及增值税附加费用、印花税预计为人民币9,273,526元（最终 金额以税务部门最终核算为准）由长沙经开投控代缴至税务机关。 本次交易不构成关联交易、亦不构成《上市公司重大资产重组管理办法》 规 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-063 天津瑞普生物技术股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津瑞普生物技术股份有限公司（以下简称"公司"）于 2023 年 6 月 26 日 召开 2023 年第一次临时股东大会，审议通过了《关于回购注销 2022 年限制性股 票激励计划部分限制性股票的议案》《关于修改公司章程的议案》，回购注销公 司 2022 年限制性股票激励计划部分限制性股票 1,742,600 股，注销完成后，公司 总股本由 468,018,786 股减至 466,276,186 股，注册资本由 468,018,786 元减至 466,276,186 元。具体内容详见公司在深圳证券交易所网站（http://www.szse.cn） 及巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 近日，公司完成了上述事宜的工商变更登记手续，并取得了由中国（天津） 自由贸易试验区市场监督管理局换发的《营业执照》。公司本次变更涉及注册资 本减少 ...

证券代码:300119 证券简称:瑞普生物 公告编号:2023-060 1 天津瑞普生物技术股份有限公司 关于参加"2023 年度天津辖区上市公司半年报业绩说明会暨投 资者网上集体接待日"活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误 导性陈述或重大遗漏。 为进一步加强与投资者的互动交流,天津瑞普生物技术股份有限公司(以下 简称"公司")将参加由天津证监局、天津上市公司协会与深圳市全景网络有限 公司联合举办的"2023 年度天津辖区上市公司半年报业绩说明会暨投资者网上 集体接待日活动",现将相关事项公告如下: 本次活动将采用网络远程的方式举行,投资者可登录"全景路演"网站 (http://rs.p5w.net),或关注微信公众号:全景财经,或下载全景路演 APP, 参与本次互动交流,活动时间为 2023 年 9 月 5 日(周二)13:30-16:50。 届时公司董事长李守军先生、董事会秘书谢刚先生、财务负责人李改变女士 将在线就公司业绩、公司治理、发展战略、经营状况和可持续发展等投资者关心 的问题,与投资者进行沟通与交流,欢迎广大投资者踊跃参与! 特此公告。 天津瑞普 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2023-058 天津瑞普生物技术股份有限公司 关于对外投资暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、对外投资暨关联交易概述 天津瑞普生物技术股份有限公司（以下简称"公司"）拟参与天津瑞嘉股权投 资合伙企业（有限合伙）（以下简称"瑞嘉基金"）基金份额扩募，瑞嘉基金认缴 规模由 2,000 万元扩募至 8,000 万元。其中，公司以自有资金 2,140 万元参与本 次认缴，完成后公司认缴总额由 1,780 万元增至 3,920 万元，占瑞嘉基金总出资 额的 49%。瑞嘉基金普通合伙人天津瑞晟私募基金管理有限公司为公司的关联 法人，本次对外投资构成关联交易。具体内容详见公司于 2023 年 8 月 21 日在巨 潮资讯网披露的《关于对外投资暨关联交易的公告》（公告编号：2023-045）。 二、对外投资暨关联交易进展情况 近日，瑞嘉基金已完成相关工商变更登记手续，并取得中国（天津）自由贸 易试验区市场监督管理局换发的营业执照，相关信息如下： 类型：有限合伙企业 执行事务合伙人：天 ...

证券代码：300119 证券简称：瑞普生物 天津瑞普生物技术股份有限公司投资者关系活动记录表 编号：2023-004 | 投资者关系活动 | 特定对象调研 分析师会议 □媒体采访 业绩说明会 | | --- | --- | | 类别 | □新闻发布会 路演活动 现场参观 | | |  其他 （电话及网络远程会议） | | 参与单位名称 | Allianz Global Investors Luxembourg S.A、Goldman Sachs、 | | | 宝盈基金、北京信伟达资管、北京颐和久富投资、北信瑞丰投 | | | 研、财通基金、财信吉祥人寿保险、大成基金、淡水泉、德邦 | | | 证券、鼎晖投资咨询、东方证券、东兴证券、方正证券、光大 | | | 证券资管、广发证券、国海证券、国信证券、华安证券、华创 | | | 证券、华泰证券、华西银峰投资、嘉实基金、建信养老、进化 | | （57 家） | 论资产、开源证券、路博迈投资、农银汇理、前海人寿、青岛 | | | 朋元资管、山东千泰私募、上海兆天投资、太平洋证券、泰达 | | | 宏利、天风证券、万和证券、西部证券、西南证券、新华基金、 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2023, representing a 20% year-over-year growth[16]. - The company's operating revenue for the reporting period was ¥994,096,256.27, representing a year-on-year increase of 9.44%[22]. - The net profit attributable to shareholders was ¥178,271,133.74, reflecting a growth of 27.49% compared to the same period last year[22]. - The net cash flow from operating activities increased significantly by 114.06%, amounting to ¥136,759,279.75[22]. - The basic earnings per share rose to ¥0.3843, a 27.00% increase from the previous year[22]. - The total assets at the end of the reporting period were ¥6,112,587,834.78, showing a slight increase of 0.10% from the end of the previous year[22]. - The company achieved operating revenue of 994.10 million yuan, an increase of 9.44% compared to the same period last year[69]. - The net profit attributable to the parent company was 178.27 million yuan, up 27.49% year-on-year[69]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 152.50 million yuan, reflecting a growth of 28.36% year-on-year[69]. Market Expansion and Strategy - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 25% based on new product launches and market expansion strategies[16]. - The company is actively pursuing market expansion, targeting new regions in Southeast Asia, with plans to establish partnerships with local distributors[16]. - A strategic acquisition of a smaller biotech firm is in progress, which is anticipated to enhance the company's product portfolio and increase market share by 10%[16]. - The company plans to enhance its digital marketing efforts, aiming to increase online sales by 30% in the upcoming quarters[16]. - The company aims to cover 1,500 key poultry farming counties and 1,000 key livestock farming counties, focusing on small-scale farms and cooperatives[46]. - The company is focusing on new product development and market expansion, particularly in the pet health sector[69]. - The company is actively pursuing market expansion through strategic partnerships in the biotechnology sector[187]. Research and Development - Research and development efforts have led to the introduction of two new vaccine products, expected to contribute an additional 50 million RMB in revenue by the end of the year[16]. - The company has a robust R&D model with multiple national and provincial innovation platforms, focusing on major animal diseases and key technologies[51]. - The company has developed multiple key technology platforms, including high-density fermentation and new adjuvant platforms, enhancing product core competitiveness[60]. - The company has established strategic partnerships with over 30 renowned research institutions, facilitating long-term collaboration in research and development[59]. - R&D investment amounted to 97.88 million yuan, accounting for 9.85% of operating revenue[70]. - The company obtained three new veterinary drug registration certificates and 25 authorized patents during the reporting period[70]. - The company completed clinical trials for its cat trivalent vaccine and dog quadrivalent vaccine, with the cat vaccine filling a domestic market gap[71][72]. Product Development and Innovation - The company has developed a trivalent inactivated vaccine for avian influenza (H5N2rHN5801 strain + rGD59 strain) that effectively prevents the occurrence of highly pathogenic avian influenza H5 and H7 subtypes[36]. - The dual inactivated vaccine for Newcastle disease and avian influenza (H9 subtype) demonstrates high antigen content and good protective effects, with minimal side reactions[36]. - The company’s LDT3-A strain vaccine provides excellent protection against various genotypes, particularly effective against the GI-19 strain, and can be administered to chicks as young as 1-3 days[39]. - The inactivated vaccine for porcine circovirus type 2 (ZJ/C strain) features a broad antigen spectrum and high antigen content, with a long protection period and minimal side effects[39]. - The company’s new oral solution for immune modulation enhances the body's immune function and improves the efficacy of vaccines and antibiotics[39]. - The innovative enteric-coated formulation of Tilmicosin granules has a bioavailability 1.41 times higher than conventional premixes, providing better treatment for bacterial infections in pigs[39]. - The company has achieved significant technological advancements, including the use of reverse genetics and ultrafiltration techniques in vaccine production, ensuring high purity and antigen content[36]. - The company is focused on expanding its product portfolio with new vaccines and treatments for various animal diseases, enhancing its market position[39]. Financial Management and Investments - The company has maintained a strong balance sheet, with total assets reported at 1.2 billion RMB, ensuring sufficient liquidity for future investments[16]. - The total amount of raised funds is RMB 132,202.05 million, with RMB 4,522.45 million invested during the reporting period[103]. - Cumulative investment of raised funds reached RMB 71,678.78 million, with a remaining balance of RMB 626,592.72 million[105]. - The company has not changed the purpose of the raised funds, maintaining a 0.00% ratio of cumulative changes[103]. - The company has utilized RMB 45,224.53 million of the raised funds during the reporting period[105]. - The cumulative amount of raised funds used is RMB 716,787.77 million, indicating effective fund management[105]. - The company has signed construction and project contracts for the Zhong'an Biological expansion project totaling ¥209,050,000, with the main engineering construction completed and four production lines ready for operation[108]. Risk Management - The management highlighted risks including animal epidemic risks and market competition, emphasizing the need for ongoing innovation and adaptation[4]. - The company is facing risks from animal epidemics, with significant threats from diseases like African swine fever and avian influenza, which could impact its operational performance[119]. - The competitive landscape in the domestic animal medicine market is intensifying, with increasing pressure from leading companies and a long-standing dominance of imported products in the pet medicine sector[121]. - The product development cycle for veterinary drugs is lengthy and uncertain, requiring regulatory approvals that may pose risks to market entry[123]. - The company is implementing a credit management policy to mitigate risks associated with high accounts receivable, ensuring most customer debts remain within normal credit periods[126]. Corporate Governance and Social Responsibility - The company has issued its first ESG report for 2022, outlining its commitments to environmental, social, and governance practices[156]. - The company donated 100,000 yuan to a charity association for poverty alleviation efforts in Tianjin[156]. - The company contributed 20,000 yuan to the South China Agricultural University for educational development[158]. - The company sponsored various industry forums and exhibitions to promote the development of the animal protection industry[159]. - The company has established internship bases with several universities, accepting over 100 interns during the reporting period[158]. Environmental Compliance - The company’s subsidiaries are classified as key pollutant discharge units by environmental protection authorities, adhering to various environmental laws and standards[138]. - The company’s environmental permits include a discharge permit for the Tianjin Rui Pu Biological Technology Co., valid until June 11, 2025[141]. - The company has implemented a stock incentive plan, with adjustments made due to the departure of 14 incentive targets[134]. - The company has invested in environmental protection projects, including low-nitrogen combustion modifications and waste gas pollution control, to enhance pollutant treatment capabilities[151]. - The wastewater treatment process at Reap Bio's airport branch includes pre-treatment, initial sedimentation, and disinfection, meeting the "Comprehensive Wastewater Discharge Standards" (DB12/356-2018)[145]. Shareholder Structure and Management Changes - The company reported its semi-annual financial results for 2023[200]. - No significant changes in shareholder structure were noted in the half-year report[200]. - The company continues to maintain its existing shareholder base without any alterations[200]. - The report confirms stability in the ownership structure, which may positively influence investor confidence[200]. - The company appointed Xu Lei as the new General Manager on March 30, 2023, following the resignation of Li Shoujun from the position[131].

证券简称：瑞普生物 证券代码：300119 天津瑞普生物技术股份有限公司 2022 年限制性股票激励计划 （草案）（修订稿） 天津瑞普生物技术股份有限公司 二零二三年八月 2022 年限制性股票激励计划（草案）（修订稿） 声 明 本公司及全体董事、监事保证本激励计划及其摘要不存在虚假记载、误导性 陈述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责任。 截至本激励计划草案公告日，公司全部在有效期内的股权激励计划所涉及的 标的股票总数未超过本激励计划草案公告日公司股本总额的 20%。任何一名激 励对象通过全部在有效期内的股权激励计划获授的公司股票数量累计未超过本 激励计划草案公告日公司股本总额的 1%。 四、限制性股票的授予价格为 9.75 元/股。在本激励计划草案公告当日至激 励对象完成限制性股票登记期间，若公司发生资本公积转增股本、派发股票红利、 股份拆细或缩股、配股、派息等事宜，限制性股票的授予价格或授予数量将根据 本激励计划予以相应的调整。 五、本激励计划授予的激励对象总人数为 213 人，为公司公告本激励计划草 案时在公司（含下属子公司，下同）任职的董事、高级管理人员、中级管理人 员、营 ...

中国银河证券股份有限公司（以下简称"银河证券"、"保荐人"）作为天 津瑞普生物技术股份有限公司（以下简称"瑞普生物"、"公司"）2021 年向特 定对象发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等相关规定，就公司使用闲置自有资金购买理财产 品事项进行了核查。具体情况如下： 一、事项概况 瑞普生物于 2023 年 8 月 24 日召开第五届董事会第七次会议，审议通过了 《关于使用闲置自有资金购买理财产品的议案》，为进一步提高公司资金使用效 率，丰富投资产品种类和渠道，同意公司在不影响正常经营的前提下，使用不超 过 10 亿元人民币的闲置自有资金购买风险可控、流动性好的中、低风险理财产 品，在上述额度及期限内，资金可以滚动使用。上述额度自董事会审议通过之日 起 12 个月内有效，单笔理财产品期限最长不超过 12 个月。本事项在公司董事会 审批权限范围内，无需提交公司股东大会审议。 二、闲置自有资金购买理财产品的情况 （一）投资目的 中国银河证券股份有限公司 关于天津瑞普生物技术股份有限公司 ...